Additionally, a recent study found that TJM-2010-2, a novel MyD88 inhibitor, reduced the expression of iNOS, Arg-1, and the immunosuppressive molecule Indoleamine-2,3-Dioxygenase (IDO) by inhibiting MyD88, thus weakening tumor immune escape [32]. Here, MYD88 is linked to neoplasm.